×

Immunotherapy against several tumors, such as lung cancer, including NSCLC

  • US 9,943,579 B2
  • Filed: 06/30/2017
  • Issued: 04/17/2018
  • Est. Priority Date: 08/05/2013
  • Status: Active Grant
First Claim
Patent Images

1. A method of eliciting an immune response in a patient who has non-small cell lung carcinoma (NSCLC), lung cancer, and/or gastric cancer, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of KIQEMQHFL (SEQ ID NO:

  • 2), wherein the peptide is in a complex with an MHC molecule, and wherein the activated T cells are cytotoxic T cells produced by contacting T cells, in vitro, with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell specifically against the peptide.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×